2020 cbpd levy - case 1 - timing and treatment for 48 yo male with egfr nsclc high pdl1
Published 3 years ago • 65 plays • Length 26:13Download video MP4
Download video MP3
Similar videos
-
4:14
case based panel discussion - egfr and high pdl1 what is the role of immunotherapy in treatment?
-
8:18
case based panel discussion - egfr and high pdl-1, choosing targeted therapy or immunotherapy
-
9:49
gracecast - treatment options for patients with nsclc and high tumor pd-l1 expression
-
11:13
gracecast-091_lung-cancer_highlights 2011: the egfr axis
-
12:58
egfr inhibitor therapy in second line
-
2:35:24
onctalk 2020, connecting patients to the experts
-
10:39
gracecast - lcvl - can patients with an egfr mutation-positive advanced nsclc benefit from immunothe
-
8:17
case based panel discussion - rapid progression adenocarcinoma high pd-l1 - how do you treat?
-
6:31
gracecast - lcvl - what is the best first line treatment for patients with advanced egfr mutation-po
-
9:26
gracecast - lcvl - which patients with advanced nsclc are good candidates for first line immunothera
-
28:22
gracecast-088_lung-cancer_challenging cases in lung cancer: acquired resistance to egfr tki therapy
-
7:09
2020 ttf egfr session - qa panel preferred chemo regimen when targeted therapy options are exhausted
-
16:48
2020 ttf egfr breakout - weiss choice of frontline egfr therapies
-
5:58
gracecast - lcvl what is the current standard of care for patients with extensive stage small cell l
-
14:43
gracecast-070_lung-cancer_q&a for acquired egfr tki and re-biopsying
-
2:14
is there a role for pd l1 testing after first line treatment for advanced non small cell lung cancer
-
9:49
gracecast-001_lung-cancer_first line chemo for advanced nscl
-
3:01
immune checkpoints and pd-l1 - lcvl 2024
-
18:51
gracecast-140_lung_highlights in lung cancer, 2012: new options for egfr mutation-positive nsclc